To include your compound in the COVID-19 Resource Center, submit it here.

Generic hit for ExonHit

Biotech companies and generic drugs are not generally associated with each other. But ExonHit Therapeutics S.A. is hoping that its Phase II trial of generic pentoxifylline in amyotrophic lateral sclerosis (ALS) will both validate its technology platform and give it a marketed product.

ExonHit specializes in detecting RNA

Read the full 476 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers